Eli Lilly
-
May 02, 2022, Monday
Experimental obesity drug may be alternative to bariatric surgery
The drug maker claimed that the new drug Tirzepatide has enabled people with obesity or who are overweight to lose about 22.5 per ...
-
October 04, 2021, Monday
Cipla to sell Eli Lilly's insulin products Humalog, Trulicity in India
Only 3 firms - Novo Nordisk, Sanofi, and Eli Lilly - supply insulin to patients in the US. These three companies, commonly called ...
-
June 28, 2021, Monday
Bajaj Healthcare seeks compulsory licence for Covid-19 drug Baricitinib
Eli Lilly has granted voluntary license to 6 Indian drugmakers for Baricitinib
-
June 24, 2021, Thursday
Eli Lilly to seek FDA approval for potential Alzheimer's drug
Shares of Eli Lilly and Co. jumped more than 8%, or $18.59, to $235.69 at the opening bell Thursday.
-
June 11, 2021, Friday
Eli Lilly memo says firm did not make false statements to FDA
(Reuters) - A week before Eli Lilly disclosed to regulators that the U.S. Justice Department was investigating its New Jersey ...
-
May 19, 2021, Wednesday
BDR Pharma inks licensing pact with Eli Lilly for Covid-19 treatment drug
Drug firm BDR Pharma on Wednesday said it has inked a licensing pact with Eli Lilly and Company for the manufacturing and ...
-
May 17, 2021, Monday
Eli Lilly inks pact with Natco Pharma for Covid-19 drug baricitinib
Drug firm Eli Lilly said it has signed a voluntary licensing agreement with Natco Pharma to further expedite the availability of ...
-
May 13, 2021, Thursday
Torrent Pharma inks pact with Eli Lilly for Covid drug Baricitinib in India
Under royalty-free, non-exclusive deal, Torrent can make and sell baricitinib in India along with the US firm's other license ...
-
May 13, 2021, Thursday
Lilly signs 3 pacts to expand availability of baricitinib for Covid patient
Eli Lilly has issued additional royalty-free, non-exclusive voluntary licenses to Dr Reddy's Ltd, MSN Laboratories and Torrent ...
-
May 11, 2021, Tuesday
Eli Lilly signs licensing pact with Cipla, Sun, Lupin for Covid-19 drug
Olumiant, or Baricitinib, is an oral drug developed by US biopharmaceutical major, Incyte Corporation, and licensed to Eli Lilly
